People with Graves' disease who have a significantly enlarged thyroid gland at diagnosis are more likely to experience a return of hyperthyroidism after stopping medication.
Claim Context
Goiter size at diagnosis is strongly associated with the risk of hyperthyroidism relapse after antithyroid drug treatment in Graves' disease, with larger goiters predicting higher recurrence rates.
“El tamaño del bocio se correlacionó muy significativamente con la probabilidad de recidiva (p < 0,0001)... Goitre size was the main predictive factor for this relapse.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether goiter size consistently predicts relapse across populations and measurement methods, and define clinically useful thresholds for risk stratification.
A systematic review and meta-analysis of all prospective studies measuring goiter volume by ultrasound at diagnosis in Graves' disease patients, reporting relapse rates at 5 and 10 years, stratified by volume quartiles, adjusting for TBII status and treatment duration, with pooled hazard ratios and ROC analysis.
An RCT could test whether early intervention to reduce goiter size (e.g., with thyroxine or rituximab) lowers relapse rates in patients with large goiters.
A multicenter double-blind RCT of 400 adults with Graves' disease and goiter >50 mL, randomized to standard antithyroid drugs versus antithyroid drugs plus low-dose levothyroxine for 18 months, with primary outcome of sustained remission at 5 years defined as euthyroidism without medication and goiter volume <20 mL.
A prospective cohort study could quantify the independent predictive value of goiter volume after adjusting for TBII, age, and treatment duration.
A prospective cohort of 1000 adults with Graves' disease, measuring goiter volume by ultrasound at diagnosis and at treatment end, with annual thyroid function testing for 10 years, using multivariable Cox regression to determine hazard ratios for relapse per 10 mL increase in goiter volume.
A case-control study could compare goiter volume between patients who relapsed and those who remained in remission to assess whether larger glands are consistently linked to recurrence.
A matched case-control study of 300 patients: 150 with relapse within 5 years and 150 matched controls (age, sex, treatment duration) who remained euthyroid, comparing baseline goiter volume measured by ultrasound, adjusting for TBII levels and smoking status.
A cross-sectional study could estimate the prevalence of large goiter among patients with established relapse, but cannot determine if it preceded the relapse.
A cross-sectional survey of 500 patients with Graves' disease relapse, measuring current goiter volume and comparing it to a control group of 500 patients in sustained remission, using the same ultrasound protocol.